{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:03:27Z","timestamp":1719187407851},"reference-count":60,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.2217\/fon.14.104","type":"journal-article","created":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T15:50:48Z","timestamp":1415721048000},"page":"1967-1980","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic Approaches in Patients With Newly Diagnosed Follicular Lymphoma"],"prefix":"10.1080","volume":"10","author":[{"given":"David","family":"Aguiar-Bujanda","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario de Gran Canaria Dr Negrin, C\/Barranco de la Ballena s\/n, 35010, Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Blanco-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario de Gran Canaria Dr Negrin, C\/Barranco de la Ballena s\/n, 35010, Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Jim\u00e9nez-Gallego","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario de Gran Canaria Dr Negrin, C\/Barranco de la Ballena s\/n, 35010, Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Mori-De Santiago","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario de Gran Canaria Dr Negrin, C\/Barranco de la Ballena s\/n, 35010, Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Hern\u00e1ndez-Sosa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario de Gran Canaria Dr Negrin, C\/Barranco de la Ballena s\/n, 35010, Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saray","family":"Galv\u00e1n-Ru\u00edz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario de Gran Canaria Dr Negrin, C\/Barranco de la Ballena s\/n, 35010, Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Hern\u00e1ndez-Sarmiento","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario de Gran Canaria Dr Negrin, C\/Barranco de la Ballena s\/n, 35010, Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Saura-Grau","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario de Gran Canaria Dr Negrin, C\/Barranco de la Ballena s\/n, 35010, Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uriel","family":"Bohn-Sarmiento","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario de Gran Canaria Dr Negrin, C\/Barranco de la Ballena s\/n, 35010, Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,11,11]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265532487"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2007.1.216"},{"issue":"5","key":"e_1_3_2_7_1","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas","volume":"20","author":"Horning SJ","year":"1993","unstructured":"Horning SJ . Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas. Semin. Oncol.20 (5 Suppl. 5), 75\u201388 (1993).","journal-title":"Semin. Oncol."},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491514"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3991"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.1693"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041869"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.90140.6521"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.213"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1282"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01747-3"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8140(95)01600-L"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.05.013"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010720"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.086"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1495"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.6546"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-45"},{"issue":"2","key":"e_1_3_2_26_1","first-page":"11","article-title":"The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment","volume":"25","author":"Young RC","year":"1988","unstructured":"Young RC , LongoDL, GlatsteinE, IhdeDC, JaffeES, DevitaVTJr. The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment. Semin. Hematol.25 (2 Suppl. 2), 11\u201316 (1988).","journal-title":"Semin. Hematol."},{"issue":"292","key":"e_1_3_2_27_1","first-page":"651","article-title":"The natural history of low grade non-Hodgkin\u2019s lymphoma and the impact of a no initial treatment policy on survival","volume":"80","author":"O\u2019Brien ME","year":"1991","unstructured":"O\u2019Brien ME , EasterbrookP, PowellJet al. The natural history of low grade non-Hodgkin\u2019s lymphoma and the impact of a no initial treatment policy on survival. Q. J. Med.80 (292), 651\u2013660 (1991).","journal-title":"Q. J. Med."},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.303"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.4474"},{"issue":"21","key":"e_1_3_2_30_1","first-page":"6","article-title":"An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, nonbulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis","volume":"116","author":"Ardeshna KM","year":"2010","unstructured":"Ardeshna KM , QianW, SmithPet al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, nonbulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis. ASH Annual Meeting Abstracts116 (21), 6 (2010).","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"4","key":"e_1_3_2_31_1","first-page":"019","article-title":"Preliminary results of quality of life (QoL) analyses from the Intergroup Phase III randomised trial of rituximab vs a watch and wait approach in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma","volume":"22","author":"Ardeshna KM","year":"2011","unstructured":"Ardeshna KM , QianW, StephensRet al. Preliminary results of quality of life (QoL) analyses from the Intergroup Phase III randomised trial of rituximab vs a watch and wait approach in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma. Ann. Oncol.22 (Suppl. 4), 019 (2011).","journal-title":"Ann. Oncol."},{"issue":"21","key":"e_1_3_2_32_1","first-page":"Absrtact LBA-6","article-title":"Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): a randomized Phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma","volume":"118","author":"Kahl BS","year":"2011","unstructured":"Kahl BS , HongF, WilliamsMEet al. Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): a randomized Phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. ASH Annual Meeting Abstracts118 (21), Absrtact LBA-6 (2011).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0866"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311253292203"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.146"},{"issue":"21","key":"e_1_3_2_44_1","first-page":"2864","article-title":"Interferon maintenance prolongs remission duration after rituximab-containing induction in first-line advanced stage follicular lymphoma patients \u2013 a retrospective analysis of the German Low-Grade Lymphoma Study Group (GLSG)","volume":"116","author":"Unterhalt M","year":"2010","unstructured":"Unterhalt M , HosterE, DreylingMH, HiddemannW. Interferon maintenance prolongs remission duration after rituximab-containing induction in first-line advanced stage follicular lymphoma patients \u2013 a retrospective analysis of the German Low-Grade Lymphoma Study Group (GLSG). ASH Annual Meeting Abstracts116 (21), 2864 (2010).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.1561"},{"issue":"21","key":"e_1_3_2_48_1","first-page":"509","article-title":"Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy","volume":"122","author":"Salles GA","year":"2013","unstructured":"Salles GA , SeymourJF, FeugierPet al. Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. ASH Annual Meeting Abstracts122 (21), 509 (2013).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.8290"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.0454"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327481201900304"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.044"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6400"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.4101"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr450"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2015"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.084723"},{"key":"e_1_3_2_60_1","unstructured":"A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera\/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera\/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin\u2019s Lymphoma (GALLIUM). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01332968"},{"key":"e_1_3_2_61_1","unstructured":"Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas (MAINTAIN). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00877214"},{"issue":"21","key":"e_1_3_2_62_1","first-page":"508","article-title":"Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: results of the randomized Phase III trial SAKK 35\/03","volume":"122","author":"Taverna CJ","year":"2013","unstructured":"Taverna CJ , MartinelliG, HitzFet al. Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: results of the randomized Phase III trial SAKK 35\/03. ASH Annual Meeting Abstracts122 (21), 508 (2013).","journal-title":"ASH Annual Meeting Abstracts"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.14.104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:08Z","timestamp":1719125048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.14.104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.2217\/fon.14.104"],"URL":"https:\/\/doi.org\/10.2217\/fon.14.104","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-11-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}